Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SH) has announced that the first participant has been dosed in a Phase I clinical trial for EP-0210, a Class 1 biologic monoclonal antibody injection developed by its wholly-owned subsidiary Chengdu Yoluo Biotechnology Co., Ltd. The trial is evaluating the drug's use in treating inflammatory bowel disease. EP-0210 is a humanized IgG1 monoclonal antibody that targets human Tumor Necrosis Factor-like ligand 1A (TL1A). Its proposed indication is for inflammatory bowel disease. The therapeutic mechanism involves the high-affinity binding of EP-0210 to human TL1A, which blocks the TL1A-mediated pro-inflammatory signaling pathway. Preclinical studies indicate that EP-0210 has a clear mechanism of action, demonstrates significant efficacy in various in vivo models of inflammatory bowel disease, and exhibits a favorable safety and efficacy profile. The drug shows advantages in target activity and in vivo efficacy compared to the foreign competitor RVT-3101, which targets the same pathway, potentially offering a safe and effective new treatment option for patients with inflammatory bowel disease.